Based on the Apellis Pharmaceuticals Inc stock forecast from 16 analysts, the average analyst target price for Apellis Pharmaceuticals Inc is USD 42.48 over the next 12 months. Apellis Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Apellis Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Apellis Pharmaceuticals Inc’s stock price was USD 19.97. Apellis Pharmaceuticals Inc’s stock price has changed by -17.72% over the past week, -21.13% over the past month and -64.28% over the last year.
No recent analyst target price found for Apellis Pharmaceuticals Inc
No recent average analyst rating found for Apellis Pharmaceuticals Inc
Company Overview Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA); and Apellis Assist, a patient-focused program specifically designed to assist patients with onboarding, product training and ongoing support with pegcetacoplan treatment, and built a care educator team to connect directly with PNH patients and their caregivers to provide education and training on the use of pegcetacoplan. The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Read Less
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the ...Read More
Frequently Asked Questions About Apellis Pharmaceuticals Inc (APLS) Stock
Based on ratings from 16 analysts Apellis Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 15 buy, sell and 16 hold ratings.
Unfortunately we do not have enough data on APLS's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for APLS is USD 42.48 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on APLS's stock to indicate if its overvalued.
The last closing price of APLS's stock was USD 19.97.
The most recent market capitalization for APLS is USD 3.14B.
Based on targets from 16 analysts, the average taret price for APLS is projected at USD 42.48 over the next 12 months.
This means that APLS's stock price may go up by +112.74% over the next 12 months.
We can't find any ETFs which contains Apellis Pharmaceuticals Inc's stock.
As per our most recent records Apellis Pharmaceuticals Inc has 705 Employees.
Apellis Pharmaceuticals Inc's registered address is 100 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from Apellis Pharmaceuticals Inc's website at https://www.apellis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Apellis Pharmaceuticals Inc (APLS) Stock
Based on ratings from 16 analysts Apellis Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 15 buy, sell and 16 hold ratings.
Unfortunately we do not have enough data on APLS's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for APLS is USD 42.48 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on APLS's stock to indicate if its overvalued.
The last closing price of APLS's stock was USD 19.97.
The most recent market capitalization for APLS is USD 3.14B.
Based on targets from 16 analysts, the average taret price for APLS is projected at USD 42.48 over the next 12 months.
This means that APLS's stock price may go up by +112.74% over the next 12 months.
We can't find any ETFs which contains Apellis Pharmaceuticals Inc's stock.
As per our most recent records Apellis Pharmaceuticals Inc has 705 Employees.
Apellis Pharmaceuticals Inc's registered address is 100 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from Apellis Pharmaceuticals Inc's website at https://www.apellis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APLS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
